Protean to Present Novel Research Findings on Colorectal Cancer at AACR22
Protean BioDiagnostics identifies key molecular differences in Colorectal cancer between men and women with implications for treatment and screening.
Experts from Protean BioDiagnostics will present ground breaking research focused on identifying the molecular basis of colorectal cancer and how it differs between men and women in America at the AACR 2022 meeting in New Orleans.
Colorectal cancer is common cancer accounting for over 50,000 deaths per year in the USA. Over 4% of people will be diagnosed with colorectal cancer in their lifetime. The incidence of the disease is 30% higher in men than women, with higher incidence and mortality in black Americans. Risk factors include low economic status. The incidence of CRC cancer is increasing in young adults.
Protean BioDiagnostics conducted a complex evaluation of the molecular features in colorectal cancer and identified multiple differences between men and women. Key genes included those involved with cell signaling and immune response. The findings have implications for designing effective screening and treatments which may need to be adjusted based on the gender of the subject.
About Protean BioDiagnostics
Protean BioDiagnostics is revolutionizing modern healthcare with our Protean MAPS™ system, which integrates health screening, diagnostics, treatment guidance, and tele-medicine backed decision support.
We collaborate with physicians and health groups to support them in providing the best possible care for their patients, regardless of where they live.